An Australian research team has developed a blood-based method of analysing thousands of proteins in a single, untargeted test. This potentially enables rapid diagnosis of many rare genetic diseases.
New research highlights the potential of circulating tumor DNA (ctDNA) analysis as a non-invasive method to identify actionable biomarkers for breast cancer, enabling individualized therapies.
Certain gene alterations can serve as a prognostic and predictive biomarker for prostate cancer. Now, researchers confirm the feasibility of using NGS on this marker for precise patient stratification and treatment selection.
A new personalised oncology platform has been tested to detect circulating tumour DNA (ctDNA) in patients with lung adenocarcinoma before surgery, to predict their risk of cancer relapse.
The study findings of a team from Julius-Maximilians-Universität Würzburg (JMU) in Bavaria, Germany help to broaden the conceptual view on the DNA damage response and to link it more closely with RNA metabolism.
Chemotherapy kills cancer cells – but how? New research suggests that the mechanisms are different than previously understood. The finding will have implications for future cancer treatments.
What role should artificial life play in medicine? Researchers from Denmark and the US explore the potential of hybrid peptide-DNA nanostructures for diagnosing and treating diseases.
Scientists have designed an AI tool that can rapidly decode a brain tumor’s DNA to determine its molecular identity during surgery — critical information that can guide treatment decisions.
Genomic sequencing panels as part of personalised cancer treatment have been found to only benefit one in 20 patients they are currently used for, according to a study by CNIO.
A trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms.
Tumors sometimes seem to take on a life of their own, with cancer genes “striking out” in ring shapes. An international research team has new insights into this phenomenon.
Scientists at the University of Applied Sciences Krems (IMC Krems) show that CRISPR-Cas9 can also be used to inhibit viruses such as adenoviruses in cell cultures.
A model organism used in laboratories for the past 100 years has evolved so extensively that it may no longer be fit for purpose, according to a new study on bacterial strain Escherichia coli K-12.
According to an international group of researchers led by Leiden University Medical Center (LUMC), patients experience 30% fewer serious side effects when medication doses are tailored to their DNA.
A new approach on the genetic tool CRISPR-Cas9 could reduce the risk of unwanted mutation, making it safer for use in humans, Dutch researchers have found.
Combining single-cell data with a self-learning algorithm reveals how structural changes in chromosomes can trigger cancer. This could pave the way for personalized cancer treatments.
Researchers at the University of Tokyo have used artificial DNA to target and kill cancer cells in a completely new way. The method showed promising results against various cancers in lab tests on mice.
A collaborative study has defined five new subgroups of the most common type of blood cancer, chronic lymphocytic leukaemia (CLL), and associated these with clinical outcomes.
Dutch global DNA/RNA technology solutions provider MolGen B.V., participates in the 24th Annual Conference of the European Society for Clinical Virology (ESCV) held in Manchester, UK.
